Vaginal and vulvar cancers do not account for a large proportion of gynecologic
malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors …

Introduction: Safety and efficacy of prophylactic HPV vaccines against HPV infection and
associated cervical cancers and precursors is well documented in the literature; however …

Globally, human papillomavirus (HPV) infection is one of the most common sexually
transmitted infection. HPV is linked to at least five malignancies including vulvar, vaginal …

Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …

The relationship between the human papillomavirus (HPV) and malignancies of the uterine
cervix, vagina, and vulva has been established. The development of a quadrivalent HPV …

Objective The study aimed to determine the baseline prevalence of human papillomavirus
(HPV) types in invasive vulvar cancer (IVC) and vulvar intraepithelial neoplasia 3 (VIN 3) …

Genital human papillomavirus (HPV) infection and HPV‐associated cervical and other
anogenital cancers are significant public health problems. HPV 16 and HPV 18 are …

INTRODUCTION.: There are some 30–40 genotypes of human papillomavirus (HPV) that
cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and …

Background Cervical cancer remains a major cause of cancer death in women worldwide.
Moreover, human papillomavirus (HPV)-related disease of the urogenital tract (including …

Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …